ライフサイエンスコーパス: nucleophosmin

1 of phenotypes observed in the absence of B23/nucleophosmin.

2 a subnucleolar compartment that contains B23/nucleophosmin.

3 sting that avrainvillamide targets cys275 of nucleophosmin.

4 chaperone phosphoproteins, nucleoplasmin and nucleophosmin.

5 bility of genes, such as GAP43, p27(Kip) and nucleophosmin.

6 by somatic mutations in NPM1, which encodes nucleophosmin.

7 Nucleophosmin 1 (NPM1) acts in ribosome biogenesis, cent

8 ith the interaction of R-DPRs with nucleolar nucleophosmin 1 (NPM1) and underscore that R-DPRs intera

9 Conversely, when we focused on nucleophosmin 1 (NPM1) associated networks, NPM1 establi

10 ar accumulation of NSs and redistribution of nucleophosmin 1 (NPM1) from the nucleolus.

11 Mutations in the nucleophosmin 1 (NPM1) gene are considered a founder eve

12 eukemia (AML) is defined by mutations in the nucleophosmin 1 (NPM1) gene.

13 ns of the MLL1 gene or with mutations in the nucleophosmin 1 (NPM1) gene.

14 ding to aberrant cytoplasmic localization of Nucleophosmin 1 (NPM1) have been recently identified as

15 Nucleophosmin 1 (NPM1) is a nucleolar protein involved i

16 Nucleophosmin 1 (NPM1) is an oligomeric, nucleolar phosp

17 bset analyses revealed that AML with mutated Nucleophosmin 1 (NPM1) may particularly benefit from VPA

18 th R/R KMT2Ar acute leukemia or with AML and nucleophosmin 1 (NPM1) mutation were enrolled.

19 Nucleophosmin 1 (NPM1) mutations are associated with a f

20 of mutant level, size, and interaction with nucleophosmin 1 (NPM1) mutations remains controversial.

21 For nucleophosmin 1 (NPM1), an essential nucleolar protein,

22 onally up-regulated targets of U2AF1-S34F is Nucleophosmin 1 (NPM1), which is a major driver of myelo

23 targeting a "public" neoantigen derived from nucleophosmin 1 (NPM1), which is mutated in approximatel

24 eolar protein ZNF692 directly interacts with nucleophosmin 1 (NPM1).

25 r response by suppressing phosphorylation of nucleophosmin 1 (NPM1).

26 Here, we demonstrate that mutant nucleophosmin 1 (NPM1c) forms nuclear condensates in hum

27 olar localization, perturb nucleolar protein nucleophosmin 1 and suppress nascent protein synthesis.

28 scribe how peptides derived from the mutated nucleophosmin 1 gene (NPM1(mut)) can elicit in vitro CD4

29 er rearrangement of KMT2A or mutation of the nucleophosmin 1 gene (NPM1)(4-6).

30 NPM1 (nucleophosmin 1) is a nucleolar phosphoprotein that regu

31 eosomal CENP-A is complexed with histone H4, nucleophosmin 1, and HJURP.

32 e prognosis for relapsed or refractory (R/R) nucleophosmin 1-mutated (NPM1m) acute myeloid leukemia (

33 kemias, including KMT2A-rearranged (KMT2Ar), nucleophosmin 1-mutated (NPM1m), and NUP98-rearranged (N

34 tion of the nucleolar proteins nucleolin and nucleophosmin 1.

35 in were increased, nm23/H1, peroxiredoxin 2, nucleophosmin 1/B23, and inorganic pyrophosphatase were

36 S-like tyrosine kinase receptor-3 (FLT3) and Nucleophosmin-1 (NPM1) are most frequent alterations in

37 Nucleophosmin-1 (NPM1) is the most frequently mutated ge

38 nditions, hematopoietic precursors harboring nucleophosmin-1 (NPM1) mutation generated myeloid cells

39 and El Hajj et al independently report that nucleophosmin-1 (NPM1)-mutant leukemia is particularly v

40 cilitates chromatin transcription (FACT) and nucleophosmin-1 (previously implicated in transcriptiona

41 The presence of a mutated nucleophosmin-1 gene (NPM1(mut)) in acute myeloid leukem

42 with clinical activity in AML patients with nucleophosmin-1 mutation (NPM1m) or lysine methyltransfe

43 terogeneous nuclear ribonucleoprotein F, and nucleophosmin-1) as major proteins exposed after injury.

44 ation factor 2, protein disulfide isomerase, nucleophosmin-1, chaperonin, actin, protein tyrosine pho

45 involved in subnuclear architecture, notably nucleophosmin, a 38-kDa nucleolar phosphoprotein that is

46 induced a decrease in the phosphorylation of nucleophosmin, a major nuclear phosphoprotein, and that

47 SBDS forms a protein complex with nucleophosmin, a multifunctional protein implicated in r

48 (ALK) under the control of the promoter for nucleophosmin, a nucleolar phosphoprotein.

49 eosarcoma cells, nucleostemin interacts with nucleophosmin, a nucleolar protein believed to possess o

50 tive effects, binds to the nuclear chaperone nucleophosmin, a proposed oncogenic protein that is over

51 e the anaplastic lymphoma kinase (ALK), with nucleophosmin-ALK (NPM-ALK) fusions being the most commo

52 astic lymphoma kinase (ALK) fusion proteins (nucleophosmin-ALK [NPM-ALK] and other variants) are expr

53 utes a part of the oncogenic fusion proteins nucleophosmin-ALK and echinoderm microtubule-associated

54 The nucleophosmin-ALK fusion induces constitutive, ligand-in

55 Previously, nucleophosmin-ALK has been shown to activate phosphatidy

56 However, nucleolar accumulation of nucleophosmin-ALK may not be necessary for its oncogenic

57 irst discovered as the constitutively active nucleophosmin-ALK oncoprotein in anaplastic large cell l

58 resulting in aberrant expression of chimeric nucleophosmin-ALK.

59 suggest that the mTOR pathway contributes to nucleophosmin-ALK/PI3K/AKT-mediated tumorigenesis and th

60 tion t(2;5) and the resulting fusion protein nucleophosmin-anaplastic lymphoma kinase (NPM-ALK) are d

61 of the constitutively active tyrosine kinase nucleophosmin-anaplastic lymphoma kinase (NPM-ALK) expre

62 Constitutive overexpression of nucleophosmin-anaplastic lymphoma kinase (NPM-ALK) is a

63 Nucleophosmin-anaplastic lymphoma kinase (NPM-ALK) is an

64 s in the production of the nucleolar protein nucleophosmin-anaplastic lymphoma kinase (NPM-ALK) prote

65 nduces the formation of the chimeric protein nucleophosmin-anaplastic lymphoma kinase (NPM-ALK), whic

66 23;q35), resulting in aberrant expression of nucleophosmin-anaplastic lymphoma kinase (NPM-ALK).

67 ults in the generation of the fusion protein nucleophosmin-anaplastic lymphoma kinase (NPM-ALK).

68 the t(2;5)(p23;q35) and aberrantly expresses nucleophosmin-anaplastic lymphoma kinase (NPM-ALK).

69 generating an oncogenic fusion protein: the nucleophosmin-anaplastic lymphoma kinase (NPM-ALK).

70 ults in the generation of the fusion protein nucleophosmin-anaplastic lymphoma kinase (NPM-ALK).

71 The nucleophosmin-anaplastic lymphoma kinase (NPM-ALK)/phosp

72 5) that produces the fusion protein NPM-ALK (nucleophosmin-anaplastic lymphoma kinase).

73 Using nucleophosmin-anaplastic lymphoma kinase-positive (NPM-A

74 ormation mediated by the oncogenic, chimeric nucleophosmin/anaplastic lymphoma kinase (NPM/ALK) tyros

75 NPM1c, result in cytoplasmic dislocation of nucleophosmin and are associated with distinctive transc

76 t CTCF copurifies with the nucleolar protein nucleophosmin and both are present at insulator sites in

77 cell-based experiments by knocking down p53, nucleophosmin and DNA methyltransferase 1.

78 o known CRM1 substrates: mutated cytoplasmic nucleophosmin and HIV-1 Rev.

79 EXIM1 interacts with two key p53 regulators, nucleophosmin and human double minute-2 protein (HDM2),

80 ic ligands binding to cell surface nucleolin/nucleophosmin and known as HB 19 for the lead compound a

81 hen evaluated whether nucleolar proteins B23/nucleophosmin and nucleolin, previously shown to interac

82 ch stabilizes its target transcripts such as nucleophosmin and p53 mRNAs.

83 emonstrate that GRK5 phosphorylates Ser-4 in nucleophosmin and regulates the sensitivity of cells to

84 ian cells; within nucleoli it interacts with nucleophosmin and rRNA through N-terminal Lys residues,

85 ocalizes with nucleolar markers such as B23 (nucleophosmin) and fibrillarin.

86 athway involving AKT, ROCK and CDK2/Cyclin E-nucleophosmin) and in mouse tissues, and increased in vi

87 action of ARF with the nucleolar protein B23(nucleophosmin) and promotes a transient p53-independent

88 ive and stain positively with nucleolar (B23/nucleophosmin) and stem/progenitor cell markers (SPRR1A

89 de NFkappaB, interferon regulatory factor-1, nucleophosmin, and the X-box binding protein-1.

90 nes, including those for REST/NRSF, Groucho, nucleophosmin, and Ubc4/5E2.

91 In addition, B23/nucleophosmin, another nucleolar protein, did not intera

92 of protamine-DNA complexes: NAP-1, NLP, and nucleophosmin are previously characterized histone chape

93 Mutations affecting NPM1 (nucleophosmin) are the most common genetic lesions found

94 stem which identified nucleolar protein B23 (nucleophosmin) as being associated with C23.

95 such as heat shock proteins, prohibitin, or nucleophosmin, as well as to the up-regulation of NF-kap

96 Nucleophosmin B23 is a nucleolar and centrosome-associat

97 two-dimensional gels showed that the form of nucleophosmin B23 that is up-regulated in melanoma repre

98 r, hepatoma-derived growth factor (HDGF) and nucleophosmin B23 were strongly correlated with melanoma

99 Nucleophosmin (B23) is a nucleolar phosphoprotein that h

100 he translocation of p53-stabilizing protein, nucleophosmin (B23), to the PNR.

101 It has been recently shown that the nucleophosmin/B23 (NPM) gene (5q35) and a novel anaplast

102 Nucleophosmin/B23 (NPM) is a pleiotropic nucleolar prote

103 nucleolar and ribosomal proteins, including nucleophosmin/B23 (NPM), a protein thought to foster the

104 tants that do not efficiently associate with nucleophosmin/B23 are unstable and functionally impaired

105 Nucleophosmin/B23 is a major multifunctional nucleolar p

106 Nucleophosmin/B23 is a multifunctional phosphoprotein th

107 The association of autoantibodies to nucleophosmin/B23 with pulmonary hypertension in sclerod

108 NPM (nucleophosmin/B23) is a major nucleolar protein which is

109 nd the hepatocellular carcinoma autoantigen, nucleophosmin/B23, as a model system to define the uniqu

110 In contrast, the nucleolar protein nucleophosmin/B23, which binds to p19Arf with high stoic

111 is identified altered expression of NEK2 and nucleophosmin/B23.

112 Moreover, we found that B23/nucleophosmin binds SENP3 and SENP5 in Xenopus laevis eg

113 ffinity-isolation of a protein identified as nucleophosmin by MS sequencing and Western-blotting.

114 f the three cysteine residues of a truncated nucleophosmin coexpressed with native nucleophosmin in C

115 Specific knockdown of nucleophosmin expression using RNAi attenuated apoptosis

116 are basic functions with, the nucleoplasmin/ nucleophosmin family of molecular chaperone proteins.

117 MO deconjugation may be a major facet of B23/nucleophosmin function in vivo.

118 e tyrosine kinase 3 gene (Flt3(ITD)) and the nucleophosmin gene (Npm1(c)) to induce AML in vivo, and

119 Mutations in the nucleophosmin gene (NPM1(mut)) are one of the most frequ

120 leukaemia 1 gene (KMT2Ar) or mutation of the nucleophosmin gene (NPM1) require the chromatin adapter

121 Frameshift mutations in exon 12 of the nucleophosmin gene (NPM1) result in aberrant cytoplasmic

122 ma kinase (ALK) receptor tyrosine kinase and nucleophosmin genes.

123 causing aberrant cytoplasmic localization of nucleophosmin have been demonstrated to be the most freq

124 idic, synthetic small molecules that bind to nucleophosmin have not been described, prior to this rep

125 ations, and that siRNA-promoted depletion of nucleophosmin in a population of HeLa S3 cells leads to

126 the similarity of Npm3 to nucleoplasmin and nucleophosmin in amino acid sequence, protein features,

127 ncated nucleophosmin coexpressed with native nucleophosmin in COS-7 cells revealed that the mutation

128 n localization determines the specificity of nucleophosmin in sorting nascent ribosomal subunits and

129 Considering the involvement of mutant nucleophosmin in the progression and maintenance of AML,

130 udy, we examined the underlying mechanism of nucleophosmin induction and showed that hyperproliferati

131 ctivation, as rapamycin completely prevented nucleophosmin induction.

132 In particular, nucleophosmin interacts with nucleolar components of new

133 Nucleophosmin is a classic mitogen-induced protein, with

134 Protein B23/nucleophosmin is a multifunctional protein that plays ro

135 B23/nucleophosmin is an abundant shuttling phosphoprotein, w

136 Nucleophosmin is commonly both over-expressed and mutate

137 Among other effects, nucleophosmin is known to regulate the tumor suppressor

138 ereas its nucleolar phosphoprotein inhibitor nucleophosmin is up-regulated.

139 B23 (NPM/nucleophosmin) is a multifunctional nucleolar protein an

140 We find that the Schizosaccharomyces pombe nucleophosmin-like protein Fkbp39 localizes to rDNA site

141 echanistic link between TSC1/mTOR signaling, nucleophosmin-mediated nuclear export of ribosome subuni

142 on through increased translation of existing nucleophosmin mRNAs.

143 However, the oncogenic potential of this nucleophosmin mutant (NPMc+) has never been established,

144 2A (KMT2A or MLL1)-rearranged (KMT2A-r) and nucleophosmin-mutant (NPM1c) acute myeloid leukemia (AML

145 Nucleophosmin-mutated acute myeloid leukemia (NPM1mut-AM

146 FLT3 internal tandem duplication (ITD) and nucleophosmin mutations occurred at a similar frequency

147 y, involving interferon regulatory factor-1, nucleophosmin, NFkappaB, and CRE binding in cell surviva

148 Nucleophosmin (NPM) (B23) is an essential protein in mou

149 The resulting nucleophosmin (NPM) /ALK chimeric kinase is constitutive

150 Here we show that nucleophosmin (NPM) acts as a natural repressor of p53 b

151 We recently identified nucleophosmin (NPM) and anaplastic lymphoma kinase (ALK)

152 Moreover, nucleophosmin (NPM) and c-Myc, both of which are commonl

153 anslocation that forms a fusion gene between nucleophosmin (NPM) and MDS/myeloid leukemia factor 1 (M

154 A fusion gene between nucleophosmin (NPM) and myelodysplasia/myeloid leukemia

155 eport the purification and identification of nucleophosmin (NPM) and nucleolin as two genotoxic stres

156 s the center of ribosome synthesis, with the nucleophosmin (NPM) and p19(ARF) proteins antagonizing o

157 part, on their ability to keep low levels of nucleophosmin (NPM) and p53 mRNAs.

158 yelocytic leukemia (APL) fuses the genes for nucleophosmin (NPM) and the retinoic acid receptor alpha

159 ion of anaplastic lymphoma kinase (ALK) with nucleophosmin (NPM) and the subsequent expression of the

160 Recently, we identified nucleophosmin (NPM) as a key factor counteracting death

161 ing, and biochemical approaches, we identify Nucleophosmin (NPM) as a novel functional target of RASS

162 n-containing CCCTC binding factor (CTCF) and nucleophosmin (NPM) at the nucleolus.

163 le in p53-null cells by hyperphosphorylating nucleophosmin (NPM) at Thr199, as evidenced by observati

164 Nucleostemin (NS) and nucleophosmin (NPM) displayed an extremely high degree o

165 stic lymphoma kinase (ALK) gene fuses to the nucleophosmin (NPM) gene as a result of a (2;5) transloc

166 in the fusion of the ubiquitously expressed nucleophosmin (NPM) gene at 5q35 to the anaplastic lymph

167 35) chromosomal translocation that fuses the nucleophosmin (NPM) gene on chromosome 5q35 to a novel p

168 aplastic Lymphoma Kinase (ALK) gene with the Nucleophosmin (NPM) gene.

169 rming capability when truncated and fused to nucleophosmin (NPM) in the t(2;5) chromosomal rearrangem

170 Nucleophosmin (NPM) is a multifunctional protein frequen

171 Nucleophosmin (NPM) is a multifunctional protein that is

172 Nucleophosmin (NPM) is frequently overexpressed in leuke

173 Like c-Myc, multifunctional nucleophosmin (NPM) is tightly regulated during prolifer

174 inal portion of the nucleolar phosphoprotein nucleophosmin (NPM) joined to the entire cytoplasmic por

175 cid residues of the nucleolar phosphoprotein nucleophosmin (NPM) joined to the entire cytoplasmic por

176 ogenesis through increased expression of the nucleophosmin (NPM) nuclear-cytoplasmic shuttling protei

177 Differential nucleophosmin (NPM) phosphorylation is a potential early

178 consensus sequence were abolished, with the nucleophosmin (NPM) reporter gene and used them for in v

179 recruiting Rac1 and its downstream effector nucleophosmin (NPM) to rDNA.

180 es the gene for the nucleolar phosphoprotein nucleophosmin (NPM) to the retinoic acid receptor alpha

181 NS interacts with nucleophosmin (NPM), a marker of nucleolar stress with c

182 Nucleophosmin (NPM), a multifunctional nucleolar phospho

183 We hypothesized that nucleophosmin (NPM), a nucleolar phosphoprotein, is crit

184 Nucleophosmin (NPM), a nucleolar phosphoprotein, is the

185 Nucleophosmin (NPM), a predominantly nucleolar protein,

186 Nucleophosmin (NPM), a previously characterized nucleola

187 PKR-modulating proteins we report here that nucleophosmin (NPM), a protein frequently overexpressed

188 Here we show that nucleophosmin (NPM), a RNA-binding protein, binds to an

189 Nucleophosmin (NPM), an oligomeric phosphoprotein and nu

190 We also identified nucleophosmin (NPM), an RNA-binding protein, as an impor

191 the most frequently mutated genes in AML is nucleophosmin (NPM), and this is associated with low CD3

192 F inhibited the interaction between DDX5 and nucleophosmin (NPM), preventing association of DDX5 with

193 ed here indicate that the nucleolar protein, nucleophosmin (NPM), redistributes from the nucleolus fo

194 nalysis of CXCR4 immune complexes identified nucleophosmin (NPM), which was confirmed by reciprocal c

195 ptase polymerase chain reaction (RT-PCR) for Nucleophosmin (NPM)-ALK during treatment identifies pati

196 This approach accurately identified the nucleophosmin (NPM)-ALK fusion protein in an anaplastic

197 ority of which harbor the well-characterized nucleophosmin (NPM)-ALK fusion protein.

198 ylation is accurately recapitulated in a new nucleophosmin (NPM)-ALK transgenic mouse model of lympho

199 human cell lines, primary human tumours and nucleophosmin (NPM)-ALK-induced murine tumours demonstra

200 ssing the oncogenic chimeric tyrosine kinase nucleophosmin (NPM)-anaplastic lymphoma kinase [ALK; ALK

201 n the nucleolus share the ability to bind to nucleophosmin (NPM).

202 t compartment by a nucleolar phosphoprotein, nucleophosmin (NPM).

203 in interacts with a 40 kDa shuttling protein nucleophosmin (NPM).

204 of the anaplastic lymphoma kinase (ALK) with nucleophosmin (NPM).

205 action partner of the anti-apoptotic protein nucleophosmin (NPM).

206 ng the expression of the cell cycle promoter nucleophosmin (NPM).

207 In this study, we report that activity of nucleophosmin (NPM)/ALK chimeric protein, the dominant f

208 hat T-cell lymphoma (TCL) cells carrying the nucleophosmin (NPM)/ALK fusion protein (ALK+ TCL) strong

209 sformation caused by the oncogenic, chimeric nucleophosmin (NPM)/anaplastic lymphoma kinase (ALK) rem

210 nisms of cell transformation mediated by the nucleophosmin (NPM)/anaplastic lymphoma kinase (ALK) tyr

211 Nucleophosmin (NPM)/B23 has been implicated in the regul

212 e describe a nuclear PI(3,4,5)P(3) receptor, nucleophosmin (NPM)/B23, that mediates the antiapoptotic

213 ns of p19(Arf) with Mdm2, or separately with nucleophosmin (NPM, B23) that localizes and stabilizes p

214 ain of the multifunctional nucleolar protein nucleophosmin (Npm-N) are central to its function, with

215 We identified nucleophosmin (NPM/B23) as a substrate of CDK2/cyclin E

216 Nucleophosmin (NPM/B23) is a key regulator in the regula

217 Nucleophosmin (NPM/B23) is a multifunctional oncoprotein

218 yclin E triggers centrosome duplication, and nucleophosmin (NPM/B23) is found to be one of its target

219 Nucleophosmin (NPM/B23) is one of the phosphorylation ta

220 leus as a physical and functional partner of nucleophosmin (NPM/B23), a major nucleolar phosphoprotei

221 We have recently found that nucleophosmin (NPM/B23), a phosphoprotein primarily foun

222 of p53-independent ARF targets, we isolated nucleophosmin (NPM/B23), a protein we show is required f

223 omal biogenesis through its interaction with nucleophosmin (NPM/B23), RNA helicase DDX5 and RNA polym

224 f many cellular proteins, including Mdm2 and nucleophosmin (NPM/B23), with which p19(Arf) physically

225 inal portion of the nucleolar phosphoprotein nucleophosmin(NPM) joined to the entire cytoplasmic port

226 or fusions (18% of cases), the gene encoding nucleophosmin (NPM1) (27%), tumor-suppressor genes (16%)

227 Furthermore, the nucleolar phosphoprotein nucleophosmin (NPM1) acts as a scaffold for PIDD and is

228 ts were the same in all 3 cases, between the nucleophosmin (NPM1) and fms-related tyrosine kinase 4 (

229 ds were investigated using redistribution of nucleophosmin (NPM1) as a marker of nucleolar stress.

230 We characterize nucleophosmin (NPM1) as an abundant cell surface protein

231 We identify nucleophosmin (NPM1) as an essential regulator of 2'-O-M

232 5 is able to interact with and phosphorylate nucleophosmin (NPM1) both in vitro and in intact cells.

233 Mutation in nucleophosmin (NPM1) causes relocalization of this norma

234 Mutations in the human nucleophosmin (NPM1) gene are the most frequent genetic

235 The nucleophosmin (NPM1) gene encodes for a multifunctional

236 Nucleophosmin (NPM1) gene has been heavily implicated in

237 Mutations of the nucleophosmin (NPM1) gene, encoding for a nucleolar mult

238 Here, we show that nucleophosmin (NPM1) integrates within the nucleolus via

239 Nucleophosmin (NPM1) is a multifunctional phospho-protei

240 Nucleophosmin (NPM1) is a multifunctional protein that c

241 Nucleophosmin (NPM1) is a nucleocytoplasmic shuttling pr

242 Nucleophosmin (NPM1) is a nucleocytoplasmic shuttling pr

243 olyadenylation, the multi-functional protein nucleophosmin (NPM1) is deposited onto all cellular mRNA

244 Nucleophosmin (NPM1) is frequently mutated in acute myel

245 Nucleophosmin (NPM1) is the 46th most abundant human pro

246 Nucleophosmin (NPM1) is the most commonly mutated gene i

247 Nucleophosmin (NPM1) is the most commonly mutated gene i

248 Nucleophosmin (NPM1) mutations in acute myeloid leukemia

249 Nucleophosmin (NPM1) mutations represent an attractive t

250 ed in CN-AML patients harboring mutations in nucleophosmin (NPM1) that are associated with favorable

251 Nucleophosmin (NPM1), a nucleolar protein frequently mut

252 eoli, co-localize with the nucleolar protein nucleophosmin (NPM1), and alter the phase separation beh

253 rosine kinase 3 gene (FLT3-ITD), a wild-type nucleophosmin (NPM1), or both.

254 th lentiviruses expressing a mutated form of nucleophosmin (NPM1), referred to as NPM1c.

255 tial redistribution of the nucleolar protein nucleophosmin (NPM1).

256 Nucleophosmin (NPM1/B23) and the activating transcriptio

257 arker (e.g., a mutation in the gene encoding nucleophosmin [NPM1]) could improve prognostication by i

258 r nuclear transport include oncogenic mutant nucleophosmin (NPM1c) and mutant PI3K catalytic subunit

259 four-nucleotide duplication in the oncogene nucleophosmin (NPM1c), which creates a neoepitope presen

260 eading to aberrant cytoplasmic expression of nucleophosmin (NPMc(+)) are the most frequent genetic le

261 a cytoplasmic FA subcomplex and the leukemic nucleophosmin (NPMc).

262 AML) carrying NPM1 mutations and cytoplasmic nucleophosmin (NPMc+ AML) accounts for about one-third o

263 a-associated antigens, prototypically mutant nucleophosmin (NPMc+) that upon mutation translocates fr

264 on, all of which were dependent on efficient nucleophosmin nuclear export.

265 ia gene, promyelocytic leukemia zinc finger, nucleophosmin, nuclear matrix protein, and signal transd

266 We propose that nucleophosmin/nucleoplasmin complexes serve as chaperone

267 nactive, unphosphorylated CPC interacts with nucleophosmin/nucleoplasmin proteins, which are known to

268 tion of the CPC causes it to dissociate from nucleophosmin/nucleoplasmin.

269 Protein B23/nucleophosmin/numatrin (B23) is a key nucleolar/nuclear

270 rotein-protein interaction and verified that nucleophosmin only bound to activated conformationally a

271 not occur with two other nucleolar proteins, nucleophosmin or nucleolin.

272 some inhibition, siRNA-mediated knockdown of nucleophosmin potentiated nucleolar accumulation and inc

273 Nucleophosmin protein accumulation in the absence of Tsc

274 Nucleophosmin protein accumulation was dependent on mamm

275 Increases in nucleophosmin protein accumulation were suppressed by re

276 nic H-Ras(V12) cause tremendous increases in nucleophosmin protein expression.

277 ajor upstream inhibitor of mTOR, resulted in nucleophosmin protein induction through increased transl

278 ation and proximity assays confirmed the Bax-nucleophosmin protein-protein interaction and verified t

279 We show that NPM1 (nucleophosmin) regulates TLS via interaction with the ca

280 slocation of nascent 60S subunits toward the nucleophosmin-rich granular component.

281 , we demonstrate that overexpression of NPM (nucleophosmin) significantly suppresses 12-O-tetradecano

282 Induction of nucleophosmin through Tsc1 loss resulted in a greater po

283 ence of p53, ARF can be stabilized by NS and nucleophosmin to serve as an alternative tumor-suppresso

284 ecognized including topoisomerases I and II, nucleophosmin, Translin, EGR1, dek, pim-1, TFG, and MLL.

285 ell-based apoptosis model, demonstrated that nucleophosmin translocation from nucleolus to cytosol pr

286 cellular fractionation studies verified that nucleophosmin translocation occurred within 3 h, at a ti

287 The molecular chaperone nucleophosmin was identified as a novel Bax-binding prot

288 Affinity-isolation of nucleophosmin was inhibited in the presence of iodoaceta

289 etion of SENP3 and SENP5 or depletion of B23/nucleophosmin, we observed accumulation of SUMO proteins

290 also discuss the role of TIF-IA, COMMD1, and nucleophosmin, which are key players in this crosstalk,

291 ied including FMS-like tyrosine kinase-3 and nucleophosmin, which will enhance our ability to more ac

292 ransport of tumor suppressors (e.g., p53 and nucleophosmin) whose function is altered in cancer becau

293 n that juxtaposes the dimerization domain of nucleophosmin with anaplastic lymphoma kinase (ALK).